Covance to bring more biologics bioanalysis capacity online in 2014

Covance to bring more biologics bioanalysis capacity online in 2014

Covance has announced that its recently expanded large molecule bioanalytical space at its laboratory facility in Indianapolis will come online in late 2014.

The expansion – which Covance claims will create 100 new jobs over the next five years – is designed to cater for growing drug industry demand for early-pharma development services for biopharmaceuticals.

Deborah Keller, executive VP of Covance’s R&D labs, said that: “Doubling our large molecule capacity and enhancing a leading team with additional dedicated scientific experts with proven success in managing through these complexities will further strengthen our leadership position in a growing market.”

She added that: “Our new biologics solutions will enable us to work in closer collaboration with our clients, providing them actionable insights to help expedite their large molecule development.”

Biologics business

The contract research organization (CRO) has also appointed Mike Holsapple, past president of the society of toxicology, as its executive director of global immunotoxicology, citing the moves as a further expansion of its biologics offering.

The expansion is in keeping with other moves towards the biopharmaceutical sector that Covance made last year.

In May, Covance said it intended to further leverage its “market-leading lead optimization abilities,” following its 2009 acquisition of Eli Lilly’s Greenfield, Indiana laboratory for $50m.

The facility – which was sold off as part of Eli Lilly’s move towards a more outsourcing-focused R&D model – houses capacity for toxicology, in vivo pharmacology and other preclinical services for biopharmaceutical and small molecule drug development.

And In November, Covance partnered with Pathoquest in an accord focused on the provision of viral contaminant testing services for manufacturers of biologic drugs.

A few weeks later the CRO teamed with NeoGenomics in a deal designed to allow its biopharmaceutical industry customers to access the latter’s range of pathology and histology services.

Related News

Market access concerns are driving changes in drug delivery, says Covance's head of Market Access Services

Covance buys market access communications firm Medaxial

Covance CEO predicts 70% of trials industry will be outsourced

Covance CEO predicts 70% of trials industry will be outsourced

Covance CFO says early stage business is mostly back on track

Covance CFO says early stage business is mostly back on track

BioLegend purchases Covance’s antibody products, manufacturing biz

BioLegend purchases Covance’s antibody products, manufacturing business

Covance clinical issues persist, CEO says

Covance clinical issues normalize

Covance reports growth as LabCorp takeover looms

Increased orders for Covance quells LabCorp uncertainty, says analyst

Covance Sees Multiple Avenues for Margin Expansion, CFO Says

Covance Sees Multiple Avenues for Margin Expansion, CFO Says

Covance to expand central labs business wthrough NeoGenomics accord

Covance to expand central labs business through NeoGenomics accord

Covance demolishes unfinished $175m lab in Virginia

Covance demolishes unfinished $175m lab in Virginia

Covance Pushes Further into Biologics Development, Lead Optimization

Covance Pushes Further into Biologics Development, Lead Optimization

Covance a winner it investigator survey

Survey: Covance Leads the Pack in Investigators’ Central Labs Favourites

Central Labs Drives Covance Revenue Growth in Q2

Central Labs Drives Covance Revenue Growth in Q2

Strong Q4 for Covance: Growth in Early development, and late-stage continues 'to defy gravity'

Covance sells 'underperforming' site to LabCorp; Reports strong Q4